on Jaguar Health, Inc. (NASDAQ:JAGX)
Jaguar Health's Canalevia-CA1 Featured in PetVet Magazine
Jaguar Health, Inc. announced that Canalevia-CA1, its prescription drug for treating chemotherapy-induced diarrhea (CID) in dogs, is featured in PetVet Magazine. Canalevia-CA1 is FDA conditionally approved and the first drug of its kind for dogs. Its active ingredient is crofelemer, derived from the Croton lechleri tree. Crofelemer is also under investigation in humans for cancer therapy-related diarrhea.
Lisa Conte, Jaguar's CEO, highlighted the significance of managing related diarrhea, which impacts the treatment and quality of life in both humans and animals with cancer. Canalevia-CA1 is for dogs only and must be prescribed by a licensed veterinarian. Common side effects include decreased appetite, activity, and abdominal pain.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Jaguar Health, Inc. news